We believe bringing successful new therapies to patients in IO and I&I diseases requires more than innovation — it takes exceptional partnerships. By combining our expertise with like-minded partners, we work to deliver effective, life-changing medicines to patients worldwide.
Collaborating to Transform Treatments
We seek to collaborate with partners to advance our IO and I&I portfolio of targeted therapies
- Out-license of select pipeline assets from discovery to clinical programs
- Co-development of internal pipeline assets
- Collaborations to explore novel & innovative technologies
- Expansion of our disease cell atlas and translational technologies
Please send any inquiries by email to: bd@hifibio.com
IO Programs Available for Partnership
| Program | Discovery | Preclinical (IND) | Phase I | Phase II/III |
|---|---|---|---|---|
| Immuno-oncology | ||||
| HFB200603*BTLA Antagonist | ||||
| Emunkitug* (HFB200301) TNFR2 Agonist | ||||
| Nuvustotug (HFB301001)OX40 Agonist | ||||
| HFB200902Gal-9 Antagonist | ||||
| HFB101110CCR8 Depletor | ||||
| Immunology & Inflammation | ||||
| HFB200604BTLA Agonist | ||||
| HFB100204CXCR5 Depletor | ||||
| HFB3024KLRG1 Depletor | ||||
| HFB2025PD-1 Depletor | ||||
| HFB2027TNFR2 Agonist | ||||
| BispecificsNovel targets | ||||
| Immuno-oncology | |||
|---|---|---|---|
| Discovery | Preclinical (IND) | Phase I | Phase II/III |
| HFB200603* | BTLA Antagonist | |||
| Emunkitug* (HFB200301) | TNFR2 Agonist | |||
| Nuvustotug (HFB301001) | OX40 Agonist | |||
| HFB200902 | Gal-9 Antagonist | |||
| HFB101110 | CCR8 Depletor | |||
| Immunology & Inflammation | |||
| Discovery | Preclinical (IND) | Phase I | Phase II/III |
| HFB200604 | BTLA Agonist | |||
| HFB100204 | CXCR5 Depletor | |||
| HFB3024 | KLRG1 Depletor | |||
| HFB2025 | PD-1 Depletor | |||
| HFB2027 | TNFR2 Agonist | |||
| Bispecifics | Novel targets | |||
*As monotherapy or in combination with anti-PD-1, Tislelizumab, supply agreement with Novartis
Publications
HFB200301 HFB200603 HFB301001 Other IO Programs
